GAITHERSBURG, Md.--(BUSINESS WIRE)--Feb. 7, 2006--GenVec, Inc. (Nasdaq:GNVC) announced today the publication of results from a Phase I clinical study of its AdPEDF gene therapy in 28 patients with advanced neovascular age-related macular degeneration (AMD), a debilitating eye disorder. The findings, published in the February 2006 issue of Human Gene Therapy, showed evidence of a halt in disease progression lasting six to twelve months after patients received a single intravitreous injection of AdPEDF. There were no serious adverse events, severe ocular inflammation or dose-limiting toxicities reported.
